News

October 23, 2018October 23, 2018

OSE Seeks French Regulatory Approval for Phase 2 Trial of Tedopi in Advanced Pancreatic Cancer

News

OSE Immunotherapeutics is planning to launch a Phase 2 clinical trial to evaluate the potential of its Tedopi vaccine, alone and in combination with Opdivo (nivolumab), as a maintenance treatment ... Read more

October 19, 2018

Celyad, Horizon Discovery Group Working to Develop New CAR T-cell Therapies

News

A recent collaboration between Celyad and Horizon Discovery Group hopes to develop new off-the-shelf CAR T-cell therapies using Horizon’s short hairpin RNA (shRNA) platform. This will be Celyad’s second non-gene-edited donor-derived platform. ... Read more

October 17, 2018

Entinostat-Keytruda Combo Shows Promise in Certain NSCLC Patients who Received Prior Immune Checkpoint Therapies

News

A combination of Syndax‘s entinostat and Keytruda (pembrolizumab) has shown clinically meaningful activity in patients with non-small cell lung cancer (NSCLC) who received prior chemotherapy and a PD-1 or PD-L1 inhibitor, Phase 3 ... Read more

October 16, 2018

1st Patient Dosed in Trial of IO102-Keytruda Combo in Treating Metastatic Lung Cancer

News

IO Biotech has dosed the first patient in a clinical trial testing the safety and efficacy of IO102 in combination with Merck’s Keytruda (pembrolizumab) as a first-line treatment for patients with metastatic ... Read more

October 12, 2018

Bayer Begins Phase 1 Trial of BAY 1905254 Immunotherapy for Advanced Solid Cancers

News

Bayer has initiated patient dosing in a Phase 1 trial assessing the investigational immunotherapy BAY 1905254 in advanced solid tumors. The study is currently recruiting in Texas and plans to recruit ... Read more

October 10, 2018October 10, 2018

2 Immunologists Win Nobel Prize in Medicine for Groundbreaking Cancer Research

News

Two immunologists, James Allison of the United States and Tasuku Honjo of Japan, have won the 2018 Nobel Prize in Medicine. Allison and Honjo will share the Nobel Prize ... Read more

October 9, 2018

Sintilimab Shows Promising Response Rates in Advanced NSCLC Patients with High Mutation Burden

News

Treatment with sintilimab, Innovent‘s PD-1 inhibitor, induces high response rates in non-small cell lung cancer (NSCLC) patients who have failed at least one prior treatment, particularly in those with a ... Read more

October 5, 2018

MEDI0457 with Anti-PD-1 Therapy Shows Promise in Treating HPV-associated Head and Neck Cancer

News

An investigational cancer vaccine, MedImmune’s MEDI0457, can safely be used in combination with anti-PD-1 therapy to improve outcomes in patients with HPV-associated head and neck cancer, a study reports, ... Read more

October 3, 2018October 3, 2018

FDA Approves Libtayo, First Treatment for Advanced Cutaneous Squamous Cell Carcinoma

News

The U.S. Food and Drug Administration has approved the immune checkpoint inhibitor Libtayo (cemiplimab-rwlc) for advanced cutaneous squamous cell carcinoma (CSCC) — a type of skin cancer — making ... Read more

October 2, 2018

Boehringer Buys ViraTherapeutics’ Shares to Expand Oncolytic Virus Program

News

Boehringer Ingelheim has bought all ViraTherapeutics’ shares, acquiring the company’s oncolytic virus platform and treatment candidates. The deal totaled €210 million (almost $247 million), and was based on a stock option agreement ... Read more

Pin It on Pinterest